Tests extra chemotherapy after chemoradiation in advanced cervical cancer
Tests extra chemotherapy in adults with cervical cancer that remains after chemoradiation.
Plain-language title generated from the registry record
Registry title: The Efficacy of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer
Key facts
- Where
- Chongqing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with locally advanced cervical cancer who still have visible disease on MRI after finishing chemoradiation.
- Age
- 18 to 75 years
- Sex
- Women only
- Disease stage
- Cervical cancer stage IIb to IVa (squamous cell carcinoma, adenosquamous carcinoma or adenocarcinoma), with leftover tumour seen on MRI within 4 weeks after chemoradiation.
- Earlier treatment
- Must have finished concurrent chemoradiation with platinum-containing chemotherapy (cisplatin or carboplatin). Cannot have had targeted therapy or pelvic artery embolization.
Main reasons for not taking part
- Active or uncontrolled severe infection
- HIV positive or other immune deficiency
- Another cancer now or before
- Liver cirrhosis, serious kidney, heart or autoimmune disease
- Disease got worse after chemoradiation
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT04409860, who can take part
Where in China
- Chongqing Cancer HospitalChongqing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Chongqing University Cancer Hospital
- Trial code
- NCT04409860
- Record updated
- 11 April 2023
- Original description
The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.Read full original descriptionShow less
Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer
The aim of this trial was to evaluate the efficacy of adjuvant chemotherapy in the locally advanced cervical cancer with residual lesions after concurrent chemoradiation therapy.
Inclusion: Cervical cancer stage IIb to IVa with histopathology of squamous cell carcinoma, adenosquamous cell carcinoma, adenocarcinoma; Complete CCRT(Radiation Does: A point 85Gy(+/-10%)，B点50Gy(+/-10%)，concurrent platinum-containing chemotherapy (cisplatin or carboplatin)); MRI is performed within 4 weeks after CCRT and shows residual lesions (non-lymph node≥10mm, lymph node shortest diameter≥15mm); ECOG<2; Expected survival is longer than six months; Hb≥70g/L、WBC≥3.5×109/ L 、ANC≥1.5×109/L、PLT≥80×109/L; ALT and AST≤2×ULN, Serum creatinine≤1.5×ULN; The serum or urine pregnancy test must be negative within 7 days before enrollment for the women of childbearing age who should agree that contraception must be used during the trial.
Exclusion: A history targeted therapy or pelvic artery embolization; Complications, need to be treatment with drugs which may lead to liver or kidney injury; Activity or uncontrol severe infection; Liver cirrhosis, Decompensated liver disease; History of immune deficiency, including HIV positive or suffering from congenital immunodeficiency disease; Patients who cannot tolerate chemotherapy because of chronic renal insufficiency or renal failure; Have suffered or combined with other malignant tumor; Myocardial infarction, severe arrhythmia and NYHA (New York heart association)≥2 for congestive heart failure; Artery-enous thrombosis within 6 months; Patients with autoimmune diseases; Patients with disease progression after chemoradiation.